Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

NCT ID: NCT04196465

Last Updated: 2025-04-10

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-09-09
• Study Completion Date: 2026-09-26

Brief Summary

This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated with two cycles of neoadjuvant immune checkpoint inhibitor of IMC-001 (1 cycle = 2 weeks) followed by curative resection and be followed up consecutively.

Detailed Description

This is a phase II, open-label, prospective single-centered study. Subjects who meet the inclusion/exclusion criteria will be allocated to appropriate cohorts: 1) gastric cancer, 2) esophageal cancer and 3) hepatocellular carcinoma. Each cancer cohort group will be treated with two cycles of neoadjuvant immune checkpoint inhibitor of IMC-001 (1 cycle = 2 weeks) followed by curative resection and be followed up consecutively.

The sample size of the study is determined based on a major pathologic response rate (primary endpoint) and by using Simon's single stage design from the subjects who receive preoperative neoadjuvant therapy of IMC-001.

In each cancer cohort group, the null and alternative response rates are assumed as 5% and 20%, respectively. This provides a power of 80% when calculating the difference between major pathologic response rates of 5% and 20% in two-tailed significance level of 0.153 (Type I error[two-tailed] of 15.3%). In order to reject the null hypothesis, at least two major pathological respondents are needed among 14 assessable subjects for each cancer cohort. After choosing the margin of safety as 10%, each cancer cohort will require 16 subjects and therefore a total of 48 subjects will be enrolled into the study.

Conditions

Subjects With Resectable and Localized Gastric Cancer; Subjects With Resectable Esophageal Cancer or Liver Cancer; Subjects With Resectable Liver Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Neoadjuvant IMC-001

Neoadjuvant immune check point inhibitor of IMC-001 in participants with resectable and localized gastric cancer, esophageal cancer, and hepatocellular carcinoma

Group Type: EXPERIMENTAL

IMC-001

Intervention Type: DRUG

IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys

Interventions

IMC-001

IMC-001 is a fully human anti-programmed cell death ligand 1 (PD-L1) recombinant monoclonal antibody that strongly binds to PD-L1 to inhibit its binding to programmed cell death protein 1 (PD-1) or B7-1 (CD80). IMC-001 showed robust dose-dependent efficacy in animal models and no evidence of toxicity in cynomolgus monkeys

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically confirmed localized gastric adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma or clinically diagnosed hepatocellular carcinoma according to American Association for the Study of Liver Disease (AASLD) guidelines.However, in cases of hepatic carcinoma that can be clinically diagnosed according to AASLD guideline, no biopsy is performed.

2. Curatively resectable gastric adenocarcinoma, esophageal squamous cell carcinoma or hepatocellular carcinoma

A. Gastric adenocarcinoma: clinical stage ≥T2 or regional lymph node metastasis (N+) (AJCC 8th)

B. Esophageal squamous cell carcinoma: clinical stage ≥T1b or N+ (AJCC 8th)

C. Hepatocellular carcinoma: a single hepatocellular carcinoma limited to liver or 3 or less hepatocellular carcinoma limited to liver without invasion to main portal trunk

3. The requirements for hematology, blood chemistry, and functionality in major organs are as follows (should be met within 7 days prior to the first administration of investigational medicinal product):

A. Absolute neutrophil count ≥1,000/μL

B. Platelets count ≥75,000/μL

C. Total bilirubin ≤1.5 × Upper limit of Normal (ULN) (subjects with Gilbert syndrome: bilirubin ≤ 3.0 × ULN)

D. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN

E. Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/minute (creatinine clearance is first calculated by the formula of Cockcroft-Gault and in case of the value less than 50 mL/min, by collecting and examining 24-hour urine the subjects with the creatine clearance ≥50 mL/minute can be enrolled) (Refer to Supplement 1).

F. Urine protein-creatinine ratio (UPC) ≤1 (in case of UPC >1, by collecting and examining 24-hour urine the subjects with the urine protein <2 g/day can be enrolled)

G. Also, in case of hepatocellular carcinoma, liver function with Child-Pugh grade A (Refer to Supplement 2) and encephalopathy grade 0.

4. Measurable or evaluable lesion(s) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Refer to Supplement 3).

5. Tumor tissue specimen, classified as appropriate for biomarker analysis, must be provided (in case of hepatocellular carcinoma, subjects, without tissue specimen prior to the administration of investigational medicinal product, are allowed for enrollment into the study).

6. Aged ≥ 19 years old

7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

8. Signed informed consent form

9. In the case of fertility men and women, Those who should be using adequate contraceptive measures while on study drug and for 3months following the last dose of study drug.

Exclusion Criteria

1. Curatively unresectable or metastatic disease

3. Patients with history of other cancers within three years prior to the study treatment. However, patients with other cancers with less influence on their prognosis such as carcinoma in situ or thyroid papillary carcinoma, in the opinion of the investigator, can be enrolled into the study.

4. History of hepatic encephalopathy.

5. Clinically significant ascites defined as follows:

A. When screening, the physical examination reveals ascites or

B. Previous ascites that required treatment and continuous prevention or current ascites that require treatment.

6. History of active autoimmune disease with systematic treatment (i.e. immunomodulator, corticosteroid, or immunosuppressant) required within the past 2 years. Replacement therapy (e.g. physiological corticosteroid replacement therapy due to dysfunction of thyroxine, insulin, adrenal gland, or pituitary gland, etc.) is not regarded as a form of systematic treatment and would be allowed.

7. Diagnosis of immunodeficiency or within 7 days prior to the first administration of investigational medicinal product treatments with chronic systematic steroids (the dose equivalent to 10 mg/day of prednisone) or immunosuppressive therapy in any other forms are not permitted.

8. History of non-infectious interstitial pneumonia requiring treatment of steroids or currently diagnosed.

9. Any prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody or other antibodies or drugs, specifically target co-stimulatory T cells or immune checkpoint pathways.

10. Any known hypersensitivity or anaphylaxis of severeness to recombinant proteins containing monoclonal antibodies.

11. Active infection with systematic treatment required.

12. From the viewpoint of the investigator, medical conditions, treatments, or laboratory test abnormalities that are likely to cause confusion in clinical trial results, or that are likely to interfere with subjects' participation throughout the entire study, or that are not considered to be in the best interests of the subjects.

13. Positive urine test or blood pregnancy test in childbearing females within 7 days prior to the first administration of investigational medicinal product.

14. Pregnant or lactating, or during the scheduled study period of 90 days after the final administration of investigational medicinal product, subjects have a plan to have conception.

15. Diagnosis of symptomatic congestive heart failure (i.e. New York Heart Association Classification class II and up) or history of clinically significant heart arrhythmia that requires other antiarrhythmic drugs other than beta blockers and digoxin, or currently diagnosed or occurrence of conduction disorders (atrial fibrillation, paroxysmal supraventricular tachycardia are exceptional) within 6 months prior to the study, active coronary artery diseases, unstable angina, new occurrence of angina within 3 months before enrollment of the study, cardiac infarction within 6 months before enrollment of the study.

16. History of human immunodeficiency virus (HIV 1/2 antibody)

17. Subjects with active hepatitis B (HBsAg-positive or detectable HBV DNA) or hepatitis C (detectable HCV RNA). Patients with hepatitis B can be enrolled in the study, only if HBV DNA <500 IU/mL (or 2500 copies/mL). Patients with positive-HCV antibody can be enrolled only if negative HCV RNA.

18. History of allogeneic tissue/solid organ transplant.

19. Inoculation with live vaccine 28 days prior to the first administration of investigational medicinal product.

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Asan Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Sook Ryun Park

Associated professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Asan Medical Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

2019-0988

Identifier Type: -

Identifier Source: org_study_id